What are the indications for discontinuation of rhGH therapy for hyposomatotropism (growth hormone deficiency [GHD])?

Updated: Jan 24, 2019
  • Author: Sunil Kumar Sinha, MD; Chief Editor: Robert P Hoffman, MD  more...
  • Print

Therapy with rhGH may need to be discontinued in patients who have acute critical conditions or illnesses, such as open heart or abdominal surgery, multiple accidental trauma, or respiratory failure. The safety of continuing rhGH treatment has not been established in patients receiving replacement doses for approved indications who concurrently develop these critical illnesses.

In a study of adults without GHD who were hospitalized for critical illness, supplemental rhGH therapy may have been associated with a significant increase in mortality rates. Jeschke et al performed a prospective, randomized, placebo-controlled study in pediatric patients hospitalized for severe burns. [71]  The mortality risk did not increase with rhGH therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!